23 Feb Mammoth Biosciences

Peter Nell, Ph.D., Chief Business Officer and Head of Therapeutics
San Francisco, CA
(Private)
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more. Mammoth’s efforts are addressed towards CRISPR-based diagnostics applying our proprietary DETECTR(TM) platform, and gene editing approaches towards ex vivo and in vivo therapeutics benefiting from our novel CRISPR systems providing unique properties. We are currently actively exploring partnerships in both areas.
www.mammoth.bio.com